Navigating well through the patent cliff
21/07/26 -"The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, and FX tailwinds. Massive generic erosion of the ..."
Pages
72
Language
English
Published on
21/07/26
You may also be interested by these reports :
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...
21/07/26
The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, ...
20/07/26
Bachem (ADD; Switzerland) is a peptide and oligonucleotide manufacturer, regarded as the most reliable partner in western economies as one of the few ...